argenx SE (ARGNF)
| Market Cap | 36.66B |
| Revenue (ttm) | 2.25B |
| Net Income (ttm) | 833.04M |
| Shares Out | n/a |
| EPS (ttm) | 12.78 |
| PE Ratio | 44.01 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1 |
| Average Volume | 33 |
| Open | 697.42 |
| Previous Close | 625.30 |
| Day's Range | 697.42 - 697.42 |
| 52-Week Range | 373.50 - 697.42 |
| Beta | 0.20 |
| RSI | 77.06 |
| Earnings Date | May 8, 2025 |
About argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ... [Read more]
Financial Performance
Financial StatementsNews
What's Driving the Market Sentiment Around argenx?
argenx's (NYSE: ARGX) short percent of float has fallen 3.8% since its last report. The company recently reported that it has 2.15 million shares sold short , which is 3.54% of all regular shares tha...
FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting
FDA approves Argenx's Vyvgart Hytrulo prefilled syringe for self-injection in gMG and CIDP, offering flexible dosing and expanding treatment options. Latest Ratings for ... Full story available on Ben...
FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting
The U.S. Food and Drug Administration (FDA) on Thursday approved a new option for patients to self-inject Argenx SE's ARGX Vyvgart Hytrulo with a prefilled syringe (efgartigimod alfa and hyaluronidase...
argenx Announces Annual General Meeting of Shareholders on May 27, 2025
April 11, 2025, 10:01 PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune d...
Argenx Bounds Off 200-Day Line On 'Best-Case Scenario' For Blockbuster Drug
Argenx stock jumped Friday after the FDA cleared its autoimmune disease drug, Vyvgart Hytrulo, for at-home treatment.
Argenx, Halozyme win FDA nod for Vyvgart Hytrulo prefilled syringe
Why Argenx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket
Shares of argenx SE (NASDAQ: ARGX) rose sharply in today's pre-market trading after the company announced the FDA approval of VYVGART Hytrulo prefilled syringe for self-injection in generalized myast...
US FDA approves syringe version of Argenx's immune disorder drug
The U.S. Food and Drug Administration has approved a pre-filled syringe version of Netherlands-based Argenx SE's blockbuster immune disorder drug, Vyvgart, giving patients the more convenient option o...
argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
VYVGART, the first-in-class FcRn blocker, now offers three administration options, including self-injection with a prefilled syringe Self-injection provides gMG and CIDP patients with flexibility for ...
Argenx's Flagship Drug Vyvgart Shows Sustained Disease Control In Rare Neuromuscular Disease Patients
Argenx SE (NASDAQ: ARGX) showcased long-term data of Vyvgart (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and hyaluronidase-qvfc) demonstrating sustained disease control of genera...
argenx SE (ARGX) Showcases Promising Data at 2025 AAN Annual Meeting
argenx SE (ARGX) Showcases Promising Data at 2025 AAN Annual Meeting
argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP
ADAPT-NXT data demonstrate consistent, sustained disease control across dosing schedules, further supporting individualized VYVGART dosing for gMG patients ADHERE+ oral presentation features long-term...
Stock Picks From Seeking Alpha's March 2025 New Analysts
In March, we welcomed 30 new analysts to Seeking Alpha, and in this article we are showcasing their stock picks and investment strategies. Our analysts covered a diverse set of industries—including IT...
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
argenx (NASDAQ: ARGX) has outperformed the market over the past 5 years by 17.3% on an annualized basis producing an average annual return of 34.95%. Currently, argenx has a market capitalization of ...
Looking Into argenx's Recent Short Interest
argenx's (NYSE: ARGX) short percent of float has risen 11.85% since its last report. The company recently reported that it has 2.23 million shares sold short , which is 3.68% of all regular shares th...
Argenx: The Magic May Be Already Priced In
Argenx is a hold due to limited catalysts in 2025, a rich valuation and clinical risk around label expansion. Read more about ARGX stock here.
P/E Ratio Insights for argenx
Looking into the current session, argenx Inc. (NASDAQ: ARGX) shares are trading at $614.18, after a 0.93% drop. Over the past month, the stock decreased by 4.88% , but over the past year, it actually...
argenx SE (ARGX) Announces Promising Data for VYVGART at AAN Annual Meeting
argenx SE (ARGX) Announces Promising Data for VYVGART at AAN Annual Meeting
argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting
Amsterdam, the Netherlands – March 7, 2025 – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, toda...
argenx targets 12,000 CIDP patients with VYVGART expansion in 2025
argenx SE (ARGX) Q4 2024 Earnings Call Transcript
argenx: Vyvgart's Sales Momentum Improves, Clinical Data Updates From A Key Competitor Imminent
Earnings Scheduled For February 27, 2025
Companies Reporting Before The Bell • Hafnia (NYSE: HAFN) is estimated to report earnings for its fourth quarter. • argenx (NASDAQ: ARGX) is projected to report quarterly earnings at $1.06 per share...
Argenx beats top-line and bottom-line estimates; initiates FY25 outlook
Argenx SE press release (ARGX): Q4 GAAP EPS of $11.79 beats by $9.92. Revenue of $736.97M (+96.9% Y/Y) beats by $27.15M. Total operating income for the three and twelve months ended
argenx SE (ARGX) Reports Strong Financial Performance and Strategic Advancements in 2024
argenx SE (ARGX) Reports Strong Financial Performance and Strategic Advancements in 2024